If you have been reading about hGH fragment and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
=== Additional effects === Semaglutide typically causes a benign increase in resting heart rate (around 3 beats per minute), which has not been associated with adverse cardiovascular events. In January 2026, the US Food and Drug Administration requested removal of suicidal behavior and ideation warning from glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications. A 2024 systematic review of 6 studies found that while lean body mass was unchanged in some cases, there were instances of significant decreases in lean body mass (0–40%). However, the review concluded that in all studies the ratio of lean body mass to total body mass increased, supporting continued use of the medication. After stopping semaglutide, individuals on average regain 67% of the weight they lost during treatment within the following year, according to a 2025 systematic review. People return to their previous weight within a year and a half on average after stopping semaglutide.
=== Gene gun === Gene gun delivery ballistically accelerates plasmid DNA (pDNA) that has been absorbed onto gold or tungsten microparticles into the target cells, using compressed helium as an accelerant.
== Cause == FECD is a degenerative disease of the corneal endothelium with accumulation of focal outgrowths called guttae (meaning a drop-like appearance) and thickening of Descemet's membrane, leading to corneal edema and loss of vision. The corneal endothelial cell layer and its basement membrane (Descemet's membrane) act as a barrier to hydration of the corneal stroma by aqueous humor and are "pump" cells of the cornea that function to maintain hydration of the cornea at a specific level that maintains corneal stromal clarity through precise spatial arrangement of collagen fibers. In FED, Descemet's membrane is grossly thickened with accumulation of abnormal wide-spaced collagen and numerous guttae. Corneal endothelial cells in end-stage FED are reduced in number and appear attenuated, causing progressive stromal edema (swelling). Progressive endothelial cell loss causes relative influx of aqueous humor into the cornea, leading to swelling (corneal stromal edema), which results in blurred vision. Eventually, the epithelium also becomes edematous, resulting in more severe visual impairment. Focal blisters of epithelial edema ("bullae") may be particularly painful when they burst. The inheritance of FECD is complex and polymorphic such that although inheritance is autosomal dominant there are genetic and environmental modifiers that determine the degree to which members of the same family express the disease. There is reasonable evidence of associations between transcription factor 4 (TCF4) genetic polymorphisms and risk of Fuchs' endothelial dystrophy (FED).
Buspirone was developed in 1968 and approved for medical use in the United States in 1986. It is available as a generic medication. In 2023, it was the 40th most commonly prescribed medication in the United States, with more than 15 million prescriptions.
Sources: en.wikipedia.org
Humboldt intended to perform trigonometric measurements on the plateau of Sisgun, but fog obscured the summit, preventing accurate results. The ascent began from the house of the mayor of Calpi, with Humboldt, Bonpland, and Montúfar proceeding on foot after the terrain became too difficult for mules. The group advanced slowly along a narrow ridge, exposed to steep drops and sharp rocks, without specialized climbing equipment. Increasing altitude brought symptoms of altitude sickness such as nausea, dizziness, and nosebleeds, while the temperature dropped and their clothing provided little protection. Despite these challenges, the party continued to conduct scientific observations. At the snow line, all but one of their Indigenous porters turned back. When the mist cleared, the summit appeared close, encouraging the climbers onward. Their progress was halted by a deep, wide crevasse filled with soft snow, which could not be crossed. Weak from the ascent and the cold, they were forced to stop. Humboldt measured their altitude at 6,428.707 yards (5,878.410 m) about 432 yards (395 m) below the summit. The group experienced a sense of isolation above the clouds, recognizing the significance of their achievement. During the descent, they encountered hail and a snowstorm that temporarily concealed the trail. As the weather improved, they observed lichen, a fly, and a butterfly above the snow line, marking the first recorded sightings of insects at such heights. The party returned to their mules shortly after two in the afternoon, concluding their attempt on Chimborazo.
== Nazi Resistance == The BRSD positioned itself squarely against National Socialism. It referred to Nazism as "pre-Christian, heathen destructive power' and criticized the ideological glorification of violence by the Nazis. As with other socialist organizations, the Federation was banned once the Nazis seized power, however, various members of the organization formed resistance groups, such as Erich Kürschner in Berlin.
More recent advances in synthetic platelet technology have focused on biomimetic approaches to replicate the essential functions of native platelets known as adhesion, aggregation, and clot formation. Platelet-mimetic nanoparticles are designed to imitate platelet behavior without the systemic risks associated with transfusion. These constructs can self-assemble into structures that bind to tumor endothelial cells and transform into nanofibers, initiating artificial coagulation at targeted sites. This ability to localize coagulation without systemic effects is being further researched for applications in treating both bleeding disorders and cancer, where controlled clotting is necessary to achieve positive patient outcomes. Emerging solutions for blood transfusions also aim to address current limitations of donor platelet products. Recent research has focused on creating synthetic platelet analogs that enable engineered constructs to selectively bind to thrombus sites, potentially enhancing the precision of clotting therapies for conditions such as thrombosis. Furthermore, integrating these platelet-mimetic features into drug delivery vehicles offers the potential for targeted therapies in cardiovascular disease, anti-inflammation treatments, and immunotherapies. Addressing safety, enhancing production methods, and managing regulatory approvals are challenges that need to be resolved before synthetic platelets can enter human clinical trial development and be routinely used in practice.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.